MONTREAL, April 7 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX : HAE), a Montreal-based specialty bio-therapeutics company, will hold its Annual General and Special Meeting of Shareholders on Wednesday, April 9, 2008 at 4 p.m. at The National Club, 303 Bay Street, Toronto, Ontario.
Mr. Joseph Galli, Chairman and Chief Executive Officer of Haemacure, will report on accomplishments of 2007 and provide an outlook for 2008 and beyond, including a report on Haemacure's clinical programs for its two proprietary, human product candidates, a fibrin sealant and an active, topical hemostatic agent (thrombin).
For those who are unable to attend in person, Haemacure will simultaneously host a live webcast of the presentation with slides, at http://events.snwebcastcenter.com/haemacure/20080409/.
Haemacure Corporation is a specialty biotherapeutics company developing
high-value human plasma-derived protein products for commercialization.
Haemacure's research and development effort is driven by its proprietary
plasma protein extraction technology to develop next-generation products,
including surgical hemostats. Haemacure's lead product candidate,
Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III
clinical trials during the first quarter of 2009. Haemacure's second
product candidate is thrombin, a component of its fibrin sealant. Follow-on
development will focus on surgical hemostats, adhesion prevention,
regenerative medecine, drug delivery and combinations with biomaterials.
Haemacure has identified eleven additional specialty proteins and enzymes
in one if its two plasma fractions and seeks to advance these proteins and
enzymes through partnerships with pharmaceutical and biotechnology
companies. Haemacure operates offices in Sarasota,
|SOURCE Haemacure Corporation|
Copyright©2008 PR Newswire.
All rights reserved